# Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

> **NCT03528902** · PHASE2 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 18 (actual)

## Conditions studied

- Hypertension
- Pulmonary Arterial Hypertension
- Familial Primary Pulmonary Hypertension
- Primary Pulmonary Hypertension
- Lung Diseases
- Tamoxifen
- Estrogen Receptor Antagonist
- Hormone Antagonists
- Estrogens

## Interventions

- **DRUG:** Tamoxifen
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03528902
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2023-06-14
- **Final completion:** 2023-06-14
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03528902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03528902, "Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03528902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*